Palo Alto, Calif. – April 22, 2026 – Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., today announced that the Paradise™ Ultrasound Renal Denervation (uRDN) system has been recognized with a TAG award in the Medical Devices: Cardiovascular Therapeutic Innovation category. The award was presented at the Medical Design & Manufacturing (MD&M) South meeting on April 22 in Charlotte, NC. The Paradise uRDN system is a device-based adjunctive therapy for patients with uncontrolled and resistant hypertension whose blood pressure cannot be properly managed with lifestyle changes and medication.
The TAG Awards celebrate innovation, achievement, and growth across MedTech, Life Sciences, BioTech, and adjacent sectors. Produced by The Aebli Group, the program recognizes companies and technologies demonstrating meaningful advancement in design, impact, execution, and market relevance through expert-led evaluation and industry-facing visibility.
“We are honored that the TAG Award committee has recognized the Paradise uRDN system. The award underscores the value of our many years of innovation and robust clinical science,” said Helen Reeve-Stoffer, Chief Operating Officer of Recor Medical. “Treatment with the Paradise uRDN system can be immensely impactful for patients with uncontrolled hypertension. It provides an important treatment alternative by which they may achieve significant reductions in blood pressure and other associated long-term benefits.”
“Congratulations to Recor for advancing a novel, patient-centered solution to a widespread and often difficult-to-manage condition,” noted one Program Judge in their anonymous evaluation. “Their work reflects a strong commitment to innovation, improved patient outcomes, and reducing the burden of chronic disease, particularly for individuals who struggle with resistant hypertension or medication adherence.”
About the Paradise uRDN System
The Paradise uRDN system is a novel ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves. The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.
The Paradise uRDN system is currently commercially available for patients in the U.S. having received FDA approval in November 2023. The Paradise Ultrasound Renal Denervation system (Paradise system) is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. Potential procedure-related adverse events including pain, vascular access site complications, and vasospasm are most common. Individual results may vary.
About Recor Medical, Inc.
Recor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd. headquartered in Palo Alto, Calif., is a medical technology company dedicated to transforming the management of treatment resistant hypertension through the Paradise™ Ultrasound Renal Denervation (uRDN). The Paradise uRDN system is FDA approved for sale in the United States, CE marked and approved in markets where the CE mark is accepted, and authorized for marketing and manufacturing in Japan, per approved indications for use. Clinical evidence for the Paradise uRDN system includes positive outcomes in three independent, randomized, sham-controlled studies in patients with mild-to-moderate and resistant hypertension. In addition, Recor is advancing real-world evidence generation through the Global Paradise System (“GPS”) Registry in the European Union and the UK, as well as the US GPS post-approval study in the United States.
https://www.recormedical.com/
About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).
https://www.omd.otsuka.com/en/
Media Contact
Lisa Owens
The Mullings Group
lowens@mullingsgroup.com
+1-210-601-6647